Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940196 | 0.86 | ADORA2A (0.50) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL940721 | 0.86 | KDM4E (0.45) | HRH4HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL1414428 | 0.85 | KDM4E (0.47) | KDM4ENCF1 | |
| SCHEMBL940619 | 0.83 | POLB (0.49) | KDM4ESMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL1414292 | 0.81 | ALDH1A1 (0.38) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL940647 | 0.78 | HTR6 (0.56) | HRH4HTR3AHTR6DRD2HTR2C | |
| SCHEMBL1414641 | 0.73 | KDM4E (0.47) | KDM4ENCF1 | |
| SCHEMBL939940 | 0.72 | IKBKB (0.42) | KDM4ESMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL27909494 | 0.72 | KDM4E (0.48) | HTR3AKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL940655 | 0.71 | ADORA2A (0.47) | KDM4ENPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1663982-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005009969-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | HRH4 209/4885HTR3A 16/4885KDM4E 3817/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | HRH4 209/4885HTR3A 16/4885KDM4E 3817/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | HRH4 631/4885HTR3A 11/4885KDM4E 4274/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | HRH4 739/4885HTR3A 21/4885KDM4E 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.